In vitro bactericidal activity of levonadifloxacin (WCK 771) against methicillin- and quinolone-resistant Staphylococcus aureus biofilms | Zendy

Melroy Tellis | Zendy; Jiji Joseph | Zendy; Hemant Khande | Zendy; Sachin Bhagwat | Zendy; Mahesh Patel | Zendy

Open Access

In vitro bactericidal activity of levonadifloxacin (WCK 771) against methicillin- and quinolone-resistant Staphylococcus aureus biofilms

Author(s) -

Melroy Tellis,

Jiji Joseph,

Hemant Khande,

Sachin Bhagwat,

Mahesh Patel

Publication year - 2019

Publication title -

journal of medical microbiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.91

H-Index - 117

eISSN - 1473-5644

pISSN - 0022-2615

DOI - 10.1099/jmm.0.000999

Subject(s) - staphylococcus aureus , biofilm , linezolid , microbiology and biotechnology , daptomycin , vancomycin , methicillin resistant staphylococcus aureus , chemistry , biology , bacteria , genetics

Staphylococcus aureus causes a wide range of infections, such as endocarditis, pneumonia, osteomyelitis, skin and soft tissue infections, and implant/in-dwelling device-related infections. S. aureus poses a significant challenge to clinicians because of its ability to rapidly acquire multi-drug resistance and quickly progress into a recurrent, chronic infection by biofilm formation. Levonadifloxacin (WCK 771) is a novel broad-spectrum antibacterial agent (it recently completed a phase 3 trial in India) with a differentiated mechanism of action involving high affinity to staphylococcal DNA gyrase, and is active against multi-drug-resistant (MDR) S. aureus, including those that are resistant to quinolones. The present study investigated the bactericidal activity of levonadifloxacin against biofilm-embedded S. aureus clinical isolates in comparison with other anti-S. aureus drugs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research